Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM
A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Medical science monitor: international medical journal of experimental and clinical research 17.6 (2011): PI15
The reluctance of health insurers is despite the predicted cost reductions due to the elimination of secondary diseases such as diabetes, knee problems, or psychological problems due to weight loss among millions of GLP 1 users
However, at this point it is not known how much absorption actually takes place with GLP-1 patches